X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1134) 1134
humans (870) 870
male (572) 572
animals (489) 489
female (446) 446
dipeptides - therapeutic use (347) 347
dipeptides - adverse effects (334) 334
dipeptides - pharmacology (324) 324
middle aged (296) 296
adult (272) 272
dipeptides - administration & dosage (216) 216
pharmacology & pharmacy (216) 216
adamantane - analogs & derivatives (209) 209
aged (209) 209
rats (202) 202
diabetes mellitus, type 2 - drug therapy (167) 167
mice (157) 157
abridged index medicus (145) 145
double-blind method (134) 134
treatment outcome (128) 128
adamantane - therapeutic use (123) 123
adamantane - adverse effects (121) 121
analysis (105) 105
endocrinology & metabolism (105) 105
saxagliptin (103) 103
dipeptidyl-peptidase iv inhibitors - therapeutic use (101) 101
dose-response relationship, drug (99) 99
type 2 diabetes (98) 98
time factors (91) 91
dipeptidyl-peptidase iv inhibitors - adverse effects (90) 90
peptides (89) 89
hypoglycemic agents - therapeutic use (87) 87
enalapril (84) 84
dipeptides - metabolism (81) 81
biochemistry & molecular biology (80) 80
drug therapy, combination (79) 79
care and treatment (77) 77
diabetes (76) 76
hypoglycemic agents - adverse effects (74) 74
research (74) 74
aspartame - adverse effects (72) 72
dipeptides - pharmacokinetics (71) 71
dipeptides (69) 69
hypertension - drug therapy (69) 69
disease models, animal (68) 68
risk factors (68) 68
dipeptides - chemistry (67) 67
metformin (67) 67
double-blind (66) 66
drug therapy (66) 66
oncology (65) 65
health aspects (64) 64
neurosciences (64) 64
proteins (61) 61
administration, oral (60) 60
expression (60) 60
glutamine (59) 59
therapy (59) 59
adolescent (58) 58
medicine, general & internal (58) 58
nutrition & dietetics (58) 58
adamantane - administration & dosage (57) 57
immunology (57) 57
medicine, research & experimental (57) 57
muramyl dipeptide (56) 56
cancer (55) 55
clinical trials (53) 53
diabetes mellitus, type 2 - blood (52) 52
safety (50) 50
cell biology (49) 49
clinical trials as topic (49) 49
lisinopril (49) 49
medicine & public health (49) 49
metabolism (49) 49
studies (49) 49
article (48) 48
dipeptidyl peptidase-4 inhibitor (48) 48
improves glycemic control (48) 48
rats, sprague-dawley (48) 48
blood pressure - drug effects (47) 47
hypoglycemic agents - administration & dosage (47) 47
internal medicine (46) 46
oxidative stress (46) 46
rats, wistar (46) 46
toxicology (46) 46
dipeptides - blood (45) 45
efficacy (45) 45
blood glucose - metabolism (44) 44
dosage and administration (44) 44
amino acids (43) 43
cardiac & cardiovascular systems (43) 43
medicine (43) 43
mice, inbred c57bl (43) 43
angiotensin-converting enzyme inhibitors (42) 42
glucose (42) 42
in-vitro (42) 42
young adult (42) 42
aged, 80 and over (41) 41
chemistry, medicinal (41) 41
dipeptidyl-peptidase iv inhibitors - administration & dosage (41) 41
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1216) 1216
Russian (18) 18
German (12) 12
Chinese (6) 6
French (6) 6
Danish (3) 3
Italian (2) 2
Norwegian (2) 2
Spanish (2) 2
Swedish (2) 2
Czech (1) 1
Dutch (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1317 - 1326
Saxagliptin, a new oral antihyperglycemic drug in the DPP-4 inhibitor class, had no effect on the risk of cardiovascular events in patients with type 2... 
ALL-CAUSE | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | GLUCOSE CONTROL | MICROALBUMINURIA | DISEASE | CLINICAL-USE | PREVENTION | RISK | DEATH | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Adamantane - therapeutic use | Aged, 80 and over | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Hypoglycemia - chemically induced | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Cardiovascular Diseases - etiology | Dipeptides - therapeutic use | Double-Blind Method | Pancreatitis - epidemiology | Dipeptides - adverse effects | Kaplan-Meier Estimate | Pancreatitis - chemically induced | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Patient outcomes | Dosage and administration | Drug therapy | Heart diseases | Risk factors | Saxagliptin | Myocardial infarction | Cerebral infarction | Heart attacks | Peptidase | Diabetes mellitus | Pancreatitis | Cardiovascular disease | Angina | Patients | Heart rate | Ischemia | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
The Lancet Oncology, ISSN 1470-2045, 06/2018, Volume 19, Issue 6, pp. 825 - 833
Journal Article
Diabetes Care, ISSN 0149-5992, 11/2015, Volume 38, Issue 11, pp. 2009 - 2017
OBJECTIVE To compare the efficacy and safety of treatment with dapagliflozin versus that with placebo add-on to saxagliptin plus metformin in patients whose... 
BODY-WEIGHT | DIPEPTIDYL PEPTIDASE-4 INHIBITOR | SULFONYLUREA | PIOGLITAZONE | EFFICACY | SAFETY | CLINICAL-TRIALS | ENDOCRINOLOGY & METABOLISM | 24-WEEK | MELLITUS | INADEQUATE GLYCEMIC CONTROL | Hypoglycemia - epidemiology | Metformin - therapeutic use | Benzhydryl Compounds - administration & dosage | Humans | Middle Aged | Male | Metformin - adverse effects | Diabetes Mellitus, Type 2 - epidemiology | Benzhydryl Compounds - adverse effects | Hypoglycemic Agents - administration & dosage | Urinary Tract Infections - chemically induced | Adamantane - therapeutic use | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Hypoglycemia - chemically induced | Glucosides - adverse effects | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Treatment Outcome | Blood Glucose - drug effects | Dipeptides - administration & dosage | Urinary Tract Infections - epidemiology | Drug Therapy, Combination - methods | Glucosides - administration & dosage | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Treatment outcome | Usage | Safety and security measures | Dapagliflozin | Analysis | Clinical trials | Dosage and administration | Metformin | Saxagliptin | Prescription drugs | Diabetes | Comparative analysis | Index Medicus
Journal Article
Journal Article
Diabetes/Metabolism Research and Reviews, ISSN 1520-7552, 2010, Volume 26, Issue 7, pp. 540 - 549
Journal Article
Diabetes Care, ISSN 0149-5992, 09/2009, Volume 32, Issue 9, pp. 1649 - 1655
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone Ralph A.... 
ORAL GLUCOSE-TOLERANCE | POTENT | MONOTHERAPY | GLUCAGON-LIKE PEPTIDE-1 | GLYCEMIC DURABILITY | INSULIN-RESISTANCE | ENDOCRINOLOGY & METABOLISM | SECRETION | MELLITUS | INHIBITOR | Metformin - therapeutic use | Humans | Middle Aged | Male | Metformin - adverse effects | Young Adult | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Placebos | Adult | Female | Metformin - administration & dosage | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Hypoglycemic Agents - therapeutic use | Adamantane - pharmacology | Dipeptides - therapeutic use | Double-Blind Method | Dipeptides - adverse effects | Dipeptides - pharmacology | Metformin - pharmacology | Treatment Outcome | Hypoglycemic Agents - pharmacology | Blood Glucose - drug effects | Dipeptides - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Diabetics | Medical research | Care and treatment | Medicine, Experimental | Glucose | Pharmaceutical industry | Dextrose | Diabetes therapy | Heart failure | Physical examinations | Drug abuse | Substance abuse treatment | Research methodology | Patient care planning | Diabetes | Safety | Drug therapy | Hypoglycemia | Apoptosis | Index Medicus | Original Research
Journal Article
Circulation, ISSN 0009-7322, 2014, Volume 130, Issue 18, pp. 1579 - 1588
Journal Article
Current Medical Research & Opinion, ISSN 0300-7995, 04/2012, Volume 28, Issue 4, pp. 513 - 523
Journal Article